"The Administration for Strategic Preparedness and Response’s (ASPR) Center for Biomedical Advanced Research and Development Authority (BARDA) is providing approximately $72 million to CSL Seqirus, Sanofi, and GSK to complete the next steps in influenza A(H5) vaccine manufacturing as part of national preparedness. (...) Separately, BARDA is providing $121.4 million to CSL Seqirus for general pandemic influenza preparedness and vendor managed inventory (VMI) of additional adjuvant of the company’s H5 influenza vaccine. Adjuvant is used in some vaccines to help create a stronger immune response for people receiving the vaccine and can allow vaccines to be made with less antigen to aid in protecting more people in an influenza pandemic."
https://aspr.hhs.gov/newsroom/Pages/ASPR-Next-Steps-Against-H5-Influenza.aspx